Whoa… completely different groups. No patients in PACIFIC were ‘operable’ by any of the neoadj trial criteria. PAC2 patients were even more advanced stage than PACIFIC, more T4 stage patients, median PTV was 450cc. Apples and watermelons my friend

Thanks to Dr. Liu and IASLC for the opportunity to explain the PAC2 trial results presented at ELCC last week! IASLC

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC @myesmo Jeff Bradley, MD Penn Medicine #ELCC24 #lcsm
onclive.com/view/concurren…

We have many ongoing trials testing the hypothesis that IO during CRT improves outcomes in Stage III unresectable lung cancer. Some have completed accrual and we await events prior to analyzing and reporting. We will get more answers.

⁦Charu Aggarwal, MD, MPH, FASCO⁩ updates us on the potential of liquid biopsies in lung cancer at ELCC 2024! ⁦ESMO - Eur. Oncology⁩ ⁦IASLC⁩ ⁦Penn Medicine⁩

Drew Moghanaki 🐕 Gerry Hanna Jeff Bradley, MD Corinne Faivre-Finn 💙 Susan Harden Fiona McDonald Patrick Forde ESMO - Eur. Oncology Gerard Walls IASLC Jarushka Naidoo Sana Karam, MD, PhD Sorry can’t conclude anything at all from this trial, will comment in separate thread but this was unfortunately too flawed to learn much from.

Dr. Jeff Bradley, MD presents results from PACIFIC-2 at #ELCC24 . Included pts with unresectable stage III NSCLC with randomization to chemoradiation with concurrent durvalumab/placebo followed by durvalumab/placebo consolidation. Note this was done before OS from PACIFIC known.

Jeff Ryckman Teoman Yanmaz Stephen V Liu, MD Do you know if PAC2 had a cross over design? I’m sure Jeff Bradley, MD can confirm. Recall, Durva isn’t a standard of care for progression during or after CRT. Those who progressed (in either arm) very likely got something else.

Happy Lung Cancer Awareness month from PennMedicine Radiation Oncology! Penn PennMedicine #AbramsonCancerCenter

Happening now in Room 1 of ASTRO #ASTRO2023 ! Excited to learn from these leading ladies in cardiotoxicity & see this in the program!

So excited to complete accrual! Many thanks to Zhongxing Liao, MD, the enrolling investigators, and the patients for their tremendous efforts! Zhongxing Liao, MD NRG Oncology

Anyone following #ProtonTherapy clinical trials knows how exciting this is! This trial has finally reached accrual due to the dedication of Zhongxing Liao, MD Jeff Bradley, MD, NRG Oncology and IROC staff, and the many participating institutions. Well done. Can’t wait to see the data!

First ever trial of proton therapy and immunotherapy for reirradiation of recurrent NSCLC. Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer
Jeff Bradley, MD Abigail T. Berman, MD, MSCE Nikhil Yegya-Raman

redjournal.org/article/S0360-…

greenlawnfuneralhome.com/obituary/carlo…
We lost a pioneer this week. Rest in peace Carlos ASTRO ASCO

Penn Radiation Oncology welcomes Dr. Jeffrey Bradley! Dr. Bradley specializes in thoracic malignancies with a focus on stereotactic body radiation therapy and proton beam therapy. Penn Medicine Jeff Bradley, MD
For more info or to refer a patient: spr.ly/6013PwrXR

Congratulations Lei! ASTRO Stanford University

Black patients remain underrepresented in clinical trials. This real-world study examines the impact of race in patients with NSCLC treated with chemoradiation and durvalumab.

🔗acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

OncoAlert
#LCSM

Meaning…. Captured in a treatment plan database. So able to query any Dx or Vx vs outcome, toxicity and/or efficacy. As you know, PACIFIC captured no RT metrics

PAC 2 collected radiotherapy planning data in a queryable database; tumor volumes, OAR doses, dose coverages, etc. There’s a lot more to this than simple PDL1 values…

This sounds like a question for the FDA.... Thinking that they will have data from multiple trials available to help decide the labels for concurrent IO + fractionated RT in NSCLC